News

An influential investment bank resumed its coverage of the company.

Iovance Biotherapeutics (IOVA) shares have been active after the company reported record second quarter revenue of nearly US$100 million and a 56% margin, alongside broader plans for its tumor infiltrating lymphocyte platform. Iovance Biotherapeutics has seen momentum build quickly, with a 90-day share price return of 162.15% and a year-to-date share price gain of 306.75%. The 1-year total shareholder return of 400% contrasts with a 5-year total shareholder return that remains down...

Iovance Biotherapeutics recently reported record second-quarter results, generating nearly US$100 million in revenue with a 56% margin, while rapidly expanding access to its Amtagvi TIL therapy across more authorized treatment centers and broader payer coverage. At the same time, the company is pushing its TIL platform beyond melanoma into lung, sarcoma, and endometrial cancers, and advancing genetically modified TIL and engineered IL-2 programs that could materially reshape its long-term...

The analyst fair value estimate for Iovance Biotherapeutics has shifted from US$9.33 to US$10.00 per share, reflecting a fresh round of updated models. Recent research points to Amtagvi revenue trends, margin progression, and the potential impact of upcoming data such as IOV-LUN-202 as key reasons behind the new cluster of price targets in the US$10 to US$15 range. Read on to see how these moves fit into the broader analyst narrative and how to track the next set of updates. Analyst Price...

Iovance Biotherapeutics has seen its stock price move sharply in recent years, which puts fresh attention on whether the current valuation lines up with the scale of its sales. For anyone looking at Iovance today, the key issue is how that share price stacks up against the revenue base supporting it. The stock has returned 400.0% over the past year, which raises a direct question about how much sales performance can underpin that kind of move. The business model, focused on developing and...

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu

CrowdStrike, Okta, and Iovance Biotherapeutics stocks surged to annual highs amid industry tailwinds and positive Wall Street outlooks.

Barclays raised Iovance’s price target to $15 from $13 while maintaining an ‘Overweight’ rating, according to The Fly.

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

Iovance executive Brian Gastman said on Tuesday at a conference that the company’s science was never the hindrance, but getting its therapy to patients.

Cellectis received a downgrade after pivoting to cardiovascular diseases therapy from a type of cancer therapy

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.

Halozyme, Repligen, Iovance, Arcutis and Precigen have been highlighted in this Industry Outlook article.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting for investors looking for earnings momentum combined with balance sheet discipline. This article examines three stocks from the Healthy high growth potential screener and explains why this blend of growth and financial strength may be appealing at this point. The stocks covered below are only a...

Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.

UBS analyst David Dai raised the firm’s price target on IOVA to $7 from $4 on Thursday while maintaining a Neutral rating.

Does Iovance Biotherapeutics (IOVA) have what it takes to be a top stock pick for momentum investors? Let's find out.

IOVA’s rally coincides with positive sentiment across melanoma-focused biotech stocks after Merck and Moderna announced successful late-stage data for their personalized mRNA cancer vaccine on Wednesday.

Investors responded to clinical progress, improving commercial performance and new growth opportunities.

Why Iovance Biotherapeutics stock is back in focus after Q2 earnings Iovance Biotherapeutics (IOVA) is back on investor radars after its second quarter 2026 earnings. The company reported higher revenue and a reduced net loss, and it reaffirmed full year revenue guidance. The quarter was driven by Amtagvi and Proleukin sales, and by progress across Iovance Biotherapeutics pipeline programs, including new regulatory approvals and Fast Track designations for lifileucel in certain soft tissue...

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

The healthcare stock is now up more than 130% this year.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

The mean of analysts' price targets for Iovance Biotherapeutics (IOVA) points to a 28% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Iovance rises 43% after Q2 results top estimates as Amtagvi sales beat forecasts, boosting revenues and prompting a review of full-year guidance.

Moby summary of Iovance Biotherapeutics, Inc.'s Q2 2026 earnings call

The rally showed that investors are paying more attention to fast-growing healthcare and digital media companies.

Iovance Biotherapeutics Inc (IOVA) reports record Q2 2026 revenue of $99.3 million, driven by strong Amtagvi demand and all-time high gross margins of 56%.